Showing promise in the arena of excess body fat therapy, retatrutide presents a distinct approach. Beyond many current medications, retatrutide works as a dual agonist, at once targeting both glucagon-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic substance (GIP) binding sites. The simultaneous stimulation encourages various helpful ef